Literature DB >> 7694153

B70 antigen is a second ligand for CTLA-4 and CD28.

M Azuma1, D Ito, H Yagita, K Okumura, J H Phillips, L L Lanier, C Somoza.   

Abstract

The membrane antigen B7/BB1 (refs 1, 2) is expressed on activated B cells, macrophages and dendritic cells, and binds to a counter-receptor, CD28, expressed on T lymphocytes and thymocytes. Interaction between CD28 and B7 results in potent costimulation of T-cell activation initiated through the CD3/T-cell receptor complex. Discrepancies between results with anti-CD28 and anti-B7 antibodies have suggested the existence of a second ligand for CD28 and CTLA-4 (refs 3, 6-8). We have generated a monoclonal antibody, IT2, that reacts with a 70K glycoprotein (B70). B70 complementary DNA was cloned from a B-lymphoblastoid cell line library and encodes a new protein of the immunoglobulin superfamily with limited homology to B7. B70 is expressed on resting monocytes and dendritic cells and on activated, but not resting, T, NK and B lymphocytes. IT2 substantially inhibited the binding of a CTLA4-immunoglobulin fusion protein to human B-lymphoblastoid cell lines and, together with anti-B7 antibody, completely blocked CTLA-4 binding. Further IT2 efficiently inhibited primary allogeneic mixed lymphocyte responses. These findings indicate that B70 is a second ligand for CD28 and CTLA-4 and may play an important role for costimulation of T cells in a primary immune response.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7694153     DOI: 10.1038/366076a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  190 in total

Review 1.  The molecular basis of T cell differentiation.

Authors:  R A Flavell
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2.

Authors:  Y Furukawa; D A Mandelbrot; P Libby; A H Sharpe; R N Mitchell
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 3.  CD28, CTLA-4 and their ligands: who does what and to whom?

Authors:  D M Sansom
Journal:  Immunology       Date:  2000-10       Impact factor: 7.397

4.  Inhibitory effects of interleukin-10 on synovial cells of rheumatoid arthritis.

Authors:  A Kawakami; K Eguchi; N Matsuoka; M Tsuboi; S Urayama; Y Kawabe; T Aoyagi; K Maeda; S Nagataki
Journal:  Immunology       Date:  1997-06       Impact factor: 7.397

5.  Marked suppression of T cells by a benzothiophene derivative in patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis.

Authors:  M Makino; M Azuma; S I Wakamatsu; Y Suruga; S Izumo; M M Yokoyama; M Baba
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

Review 6.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

7.  Characterization of CMRF-44, a novel monoclonal antibody to an activation antigen expressed by the allostimulatory cells within peripheral blood, including dendritic cells.

Authors:  B D Hock; G C Starling; P B Daniel; D N Hart
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

8.  Effect of CD28 signal transduction on c-Rel in human peripheral blood T cells.

Authors:  R G Bryan; Y Li; J H Lai; M Van; N R Rice; R R Rich; T H Tan
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

9.  Detection of circulating soluble CD28 in patients with systemic lupus erythematosus, primary Sjögren's syndrome and systemic sclerosis.

Authors:  M Hebbar; P Jeannin; G Magistrelli; P-Y Hatron; E Hachulla; B Devulder; J-Y Bonnefoy; Y Delneste
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

10.  Distinct roles for B7-1 (CD-80) and B7-2 (CD-86) in the initiation of experimental allergic encephalomyelitis.

Authors:  M K Racke; D E Scott; L Quigley; G S Gray; R Abe; C H June; P J Perrin
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.